Cyclohexyl beta-hydroxy alkyl amines and medical uses thereof
US-2024390298-A1 · Nov 28, 2024 · US
Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis
US9856210B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9856210-B2 |
| Application number | US-201113820420-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 2, 2011 |
| Priority date | Sep 2, 2010 |
| Publication date | Jan 2, 2018 |
| Grant date | Jan 2, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a prophylactic or therapeutic agent for amyotrophic lateral sclerosis, containing a 1,3-diphenylurea derivative or multikinase inhibitor.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of inhibiting the expression of human SOD1 in a cell by administering sorafenib or a pharmaceutically acceptable salt thereof to the cell, wherein the human SOD1 is mutated SOD1. 2. The method of claim 1 , wherein sorafenib is administered. 3. The method of claim 1 , wherein sorafenib tosylate is administered. 4. The method of claim 1 , wherein the cell is in a subject suffering from amyotrophic lateral sclerosis (ALS) accompanied by a mutation in SOD1. 5. The method of claim 4 , wherein sorafenib is administered. 6. The method of claim 4 , wherein sorafenib tosylate is administered.
Assignees
Inventors
Classifications
- A61K31/17Primary
having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64) · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
- C07C275/30Primary
being further substituted by halogen atoms, or by nitro or nitroso groups · CPC title
Non condensed pyridines; Hydrogenated derivatives thereof · CPC title
Muscle relaxants, e.g. for tetanus or cramps · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9856210B2 cover?
- The present invention provides a prophylactic or therapeutic agent for amyotrophic lateral sclerosis, containing a 1,3-diphenylurea derivative or multikinase inhibitor.
- Who is the assignee on this patent?
- Inoue Haruhisa, Kitaoka Shiho, Tsukita Kayoko, and 9 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/17. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).